Inicio / Gastroenterología / Abstracts de gastroenterología / Editorial: mesalazine and…

Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis—what can we learn?

0 / 5 (0 votos)
Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis—what can we learn?

Alimentary Pharmacology & Therapeutics

Fecha de publicación: 27 May 2019

DOI: https://doi.org/10.1111/apt.15281

Autores: Anna M. Buchner, Gary R. Lichtenstein

Background: Patients with IBD have an altered gut microbiome; these alterations are defined as dysbiosis. Reduced diversity, abundance of pro‐inflammatory bacteria such as Enterobacteriaceae, reduction in phyla with anti‐inflammatory properties such as Firmicutes have been reported. Mechanisms of efficacy of pharmacotherapy or markers of response and relationships to dysbiosis have been of special interest.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.